通报号: G/TBT/N/KOR/601 |
ICS号: 11.120
|
发布日期: 2015-09-04
|
截至日期: 2015-11-03
|
通报成员: 韩国
|
目标和理由: 保护消费者
|
内容概述: 扩大了生物改良药的定义,包括活性成分或剂量/用法发生变化的生物产品; 撤销了重组蛋白质产品出口免除条款,废除了评估生产管理规范(GMP)时提交至少1个生产单位的GMP记录(须提交至少3个生产单位的记录); 要求干细胞产品须经长期安全评估以加强不良事件监督及加强售后安全管理。
|
正文:
世界贸易组织 |
G/TBT/N/KOR/601
2015-09-04
15-4525
|
|
技术性贸易壁垒 |
原文:英语
|
通 报
以下通报根据TBT协定第10.6条分发
1. |
通报成员: 韩国
如可能,列出涉及的地方政府名称 ( 3.2条和7.2 条):
|
2. |
负责机构:韩国食品药品安全部(MFDS)
|
3. |
通报依据条款:5.6.2
|
4. |
覆盖的产品: 生物产品。
HS编码:30 ICS编码:11.120
|
5. |
通报标题: “生物产品审核和授权法规”修订提案
语言:韩国语 页数:14 链接网址:
|
6. |
内容简述: 扩大了生物改良药的定义,包括活性成分或剂量/用法发生变化的生物产品;
撤销了重组蛋白质产品出口免除条款,废除了评估生产管理规范(GMP)时提交至少1个生产单位的GMP记录(须提交至少3个生产单位的记录);
要求干细胞产品须经长期安全评估以加强不良事件监督及加强售后安全管理。
|
7. |
目标与理由:保护消费者健康。
|
8. |
相关文件: 韩国食品药品安全部(MFDS)通报No.2015-284(2015年8月28日)
|
9. |
拟批准日期:待定
拟生效日期:待定
|
10. |
意见反馈截止日期: 通报之后60天
|
11. |
文本可从以下机构得到:
|
|
正文(英):
NOTIFICATION
The following notification is being circulated in accordance with Article 10.6
1.
|
Notifying Member: Republic of Korea
If applicable, name of local government involved (Article 3.2 and 7.2):
|
2.
|
Agency responsible: Ministry of Food and Drug Safety
Name and address (including telephone and fax numbers, email and website addresses, if available) of agency or authority designated to handle comments regarding the notification shall be indicated if different from above:
Documents are available from the Ministry of Food and Drug safety website (http://www.mfds.go.kr)
Also available from:
International Cooperation Office
Ministry of Food and Drug Safety
187 Osongsaengmyeong2-ro, Osong-eup
Heungdoek-guCheongju-si
Chungcheongbuk-do, 363-700
Republic of Korea
Tel: (+82) 43719-1564
Fax: (+82) 43-719-1550
Email: wtokfda@korea.kr
|
3.
|
Notified under Article 2.9.2 [ ], 2.10.1 [ ], 5.6.2 [X], 5.7.1 [ ], other:
|
4.
|
Products covered (HS or CCCN where applicable, otherwise national tariff heading. ICS numbers may be provided in addition, where applicable): Biological products
|
5.
|
Title, number of pages and language(s) of the notified document: Proposed amendments to the "Regulation of Review and Authorization on Biological Products, etc." (14 pages, in Korean)
|
6.
|
Description of content:
· Expand the definition of biobetters to include biological products with changes in the active ingredient content or dosage/administration
· Delete the exemption clause for recombinant protein products for export, which would invalidate its submission of GMP records with at least one manufacturing unit when evaluating GMP (they would be subject to submitting records with at least three manufacturing units)
· Require stem-cell products to be subject to long-term safety evaluation to enhance active monitoring of adverse events and strengthen post-marketing safety management
|
7.
|
Objective and rationale, including the nature of urgent problems where applicable: Protection of consumer health
|
8.
|
Relevant documents: MFDS Notification No. 2015-284 (28 August 2015)
|
9.
|
Proposed date of adoption: To be determined
Proposed date of entry into force: To be determined
|
10.
|
Final date for comments: 60 days from notification
|
11.
|
Texts available from: National enquiry point [ ] or address, telephone and fax numbers and email and website addresses, if available, of other body:
WTO Technical Barriers to Trade(TBT) Division
Korean Agency for Technology and Standards (KATS)
93, Isu-ro, Maengdong-myeon
Eumseong-gun
Chungcheongbuk-do
Republic of Korea, 369-811
Tel.: (+82) 43 870 5525
Fax: (+82) 43 870 5682
E-mail: tbt@kats.go.kr
Website: http://www.knowtbt.kr
|
|
|
|
|
|
|
本网维权及免责声明:
①凡本网所有原始/编译文章及图片、图表的版权均属江苏省技术性贸易措施信息平台(www.tbtguide.com)所有,如要转载,需注明"信息来源:江苏省技术性贸易措施信息平台"或"信息来源:tbtguide"。违反上述规定者,本网将保留追究其侵权责任的权利。
②凡本网注明"信息来源:XXX(非tbtguide)"的作品,均转载自其他媒体,转载目的在于传递更多的信息,并不代表本网赞同其观点和对其真实性负责。
联系E-mail:js_wto@163.com |